PH12020551547A1 - Pharmaceutical preparation - Google Patents
Pharmaceutical preparationInfo
- Publication number
- PH12020551547A1 PH12020551547A1 PH12020551547A PH12020551547A PH12020551547A1 PH 12020551547 A1 PH12020551547 A1 PH 12020551547A1 PH 12020551547 A PH12020551547 A PH 12020551547A PH 12020551547 A PH12020551547 A PH 12020551547A PH 12020551547 A1 PH12020551547 A1 PH 12020551547A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical preparation
- provides
- present
- preparation
- rosuvastatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
The present invention provides a preparation containing fimasartan, amlodipine and rosuvastatin as active ingredients. The present invention provides a preparation having an excellent dissolution rate for each active ingredient and a high stability, thereby enabling the convenience of administration to be remarkably improved.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180050277A KR101992400B1 (en) | 2018-04-30 | 2018-04-30 | Pharmaceutical formulation |
PCT/KR2019/005151 WO2019212214A1 (en) | 2018-04-30 | 2019-04-29 | Pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12020551547A1 true PH12020551547A1 (en) | 2021-06-07 |
Family
ID=67055715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12020551547A PH12020551547A1 (en) | 2018-04-30 | 2020-09-24 | Pharmaceutical preparation |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR101992400B1 (en) |
CN (1) | CN112040933A (en) |
MX (1) | MX2020010259A (en) |
PH (1) | PH12020551547A1 (en) |
RU (1) | RU2756452C1 (en) |
SG (1) | SG11202009187YA (en) |
TW (1) | TWI697339B (en) |
WO (1) | WO2019212214A1 (en) |
ZA (1) | ZA202006346B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102595702B1 (en) * | 2021-06-09 | 2023-10-30 | 주식회사 보령 | Pharmaceutical composite formulation and method of preparing pharmaceutical composite formulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101336922A (en) * | 2008-08-08 | 2009-01-07 | 青岛黄海制药有限责任公司 | Rosuvastatin amlodipine composition |
RU2712757C3 (en) * | 2009-11-13 | 2021-06-09 | Астразенека Аб | TWO-LAYER TABLET COMPOSITION |
KR101058284B1 (en) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | Novel Process for the Preparation of 2- (2-N-butyl-4-hydroxy-6-methyl-pyrimidin-5-yl) -N, N-dimethylacetamide |
KR101168136B1 (en) * | 2011-08-08 | 2012-07-24 | 보령제약 주식회사 | Antihypertensive pharmaceutical composition |
PT2830618T (en) * | 2012-03-30 | 2016-11-04 | Dae Woong Pharma | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt |
CN103156842B (en) * | 2013-03-08 | 2014-05-28 | 南开大学 | Novel application of Arctigenin in preparation of anti-arrhythmia medicine |
MY174729A (en) * | 2013-03-14 | 2020-05-11 | Boryung Pharm | Pharmaceutical combination drug |
KR101910901B1 (en) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin |
WO2017007287A1 (en) * | 2015-07-08 | 2017-01-12 | 씨제이헬스케어 주식회사 | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin |
WO2017091041A1 (en) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | Novel salt of fimasartan |
-
2018
- 2018-04-30 KR KR1020180050277A patent/KR101992400B1/en active IP Right Grant
-
2019
- 2019-04-29 TW TW108114949A patent/TWI697339B/en active
- 2019-04-29 SG SG11202009187YA patent/SG11202009187YA/en unknown
- 2019-04-29 WO PCT/KR2019/005151 patent/WO2019212214A1/en active Application Filing
- 2019-04-29 CN CN201980029029.3A patent/CN112040933A/en active Pending
- 2019-04-29 MX MX2020010259A patent/MX2020010259A/en unknown
- 2019-04-29 RU RU2020138708A patent/RU2756452C1/en active
-
2020
- 2020-09-24 PH PH12020551547A patent/PH12020551547A1/en unknown
- 2020-10-13 ZA ZA2020/06346A patent/ZA202006346B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2756452C1 (en) | 2021-09-30 |
ZA202006346B (en) | 2022-01-26 |
KR101992400B1 (en) | 2019-06-24 |
MX2020010259A (en) | 2020-10-22 |
CN112040933A (en) | 2020-12-04 |
SG11202009187YA (en) | 2020-10-29 |
TW201946916A (en) | 2019-12-16 |
WO2019212214A1 (en) | 2019-11-07 |
TWI697339B (en) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792592A1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN | |
NZ764304A (en) | Novel bradykinin b2 receptor antagonists | |
MX2018003096A (en) | Pharmaceutical composition containing anionic drug, and preparation method therefor. | |
EA201792591A1 (en) | PHARMACEUTICAL PREPARATIONS | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
MX2018000546A (en) | Pharmaceutical composition containing celecoxib and tramadol. | |
MX2018000084A (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin. | |
MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
PH12020550815A1 (en) | Delayed release deferiprone tablets and methods of using the same | |
MX2017009289A (en) | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same. | |
PH12020551547A1 (en) | Pharmaceutical preparation | |
PH12017500536A1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
MX2017013633A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles. | |
MX2018010065A (en) | Oral dosage form comprising rifaximin in form beta. | |
MX2021000769A (en) | Pharmaceutical composition containing clomipramine and preparation method therefor. | |
EA201991286A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN | |
MX2017013643A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix. | |
MX2020006886A (en) | Drug delivery system. | |
MX2019015869A (en) | New oral formulations of belinostat. | |
MX2017013634A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder. | |
PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
MX2017014725A (en) | Dropropizine in combination with ambroxol in the dosage form of syrup or tablets. | |
PH12019501049A1 (en) | Pharmaceutical composition containing palonosetron as active ingredient |